SecBot SecBot

TENX

TENAX THERAPEUTICS, INC.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0000034956 Biotech & Drug Discovery
$1.64 −0.08 (−4.65%)
Oct 26 4:00 PM ET · prev $1.72
Market cap
$65.9M
Micro cap
Consensus
Buy
69% Buy or better · 16 analysts
Median target
🔒 Subscribers only
Next earnings
Nov 10
in 14 days · EPS est. −$0.36
1 year
−78.1%
from $7.50 · Oct 27
30 days
−11.4%
from $1.85
52-week range
$1.36–18.32
−91% from high · low Oct 16
Avg volume 20D
2.25M
Oct 13 spike 7.68M
Short interest
🔒 Subscribers only
Insider net
+$6.4M
4 buyers · 0 sellers · 12 mo
New fund stakes
1
Q2 2026 13F · 0 exits
Filing reports
17
analyzed by SecBot
SecBot read MIXED 11 reports · 90 days
Balance 0 bearish · 2 bullish · 3 mixed · 6 neutral oldest → newest, height = score
Avg score ·High conf. 9/11 ·Next Earnings date, Nov 10, 2026
Strongest BULLISH Sphera Funds Management Ltd. and related entities filed an amended Schedule 13G disclosing a 7.09% passive…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    4 insiders bought $6.4M at an average $1.73. No open-market sales. Price is 5% below their cost.

  • InstitutionsBULLISH

    Q2 2026: 26 added (1 new), 6 trimmed or exited. Largest new: Candriam S.C.A $10.9M.

  • AnalystsBULLISH

    11 of 16 rate it Buy or better.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.382 → −$0.360 over 90 days. 4 up, 1 down in 30 days.

  • TrendDOWNTREND

    11% below its 50-day average.

Who's buying

13F· Q2 2026
1
new positions
0
exits
$10.9M
in new stakes
FundMoveSharesValue
FMR LLCDOUBLED3,942,373$57.4M
BlackRock, Inc.DOUBLED1,727,988$25.1M
VANGUARD CAPITAL MANAGEMENT LLCDOUBLED1,147,121$16.7M
MILLENNIUM MANAGEMENT LLCADD876,230$12.7M
Candriam S.C.A.NEW749,588$10.9M
CITADEL ADVISORS LLCDOUBLED728,561$10.6M
RTW INVESTMENTS, LPADD696,570$10.1M
GEODE CAPITAL MANAGEMENT, LLCDOUBLED639,537$9.3M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

16 analysts
Buy 69% rate it Buy or better
Strong Buy3Buy8Hold5Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Aug 31, 2026Guggenheim
DOWNGRADE
DOWNGRADENeutral
Aug 11, 2026Chardan Capital
DOWNGRADE
DOWNGRADENeutral
Aug 11, 2026Canaccord Genuity
MAINTAIN
MAINTAINBuy
Aug 11, 2026Guggenheim
MAINTAIN
MAINTAINBuy
Aug 11, 2026Evercore ISI Group
DOWNGRADE
DOWNGRADEIn-Line
Aug 10, 2026William Blair
DOWNGRADE
DOWNGRADEMarket Perform

Insider ledger

Form 4
$6.4M
bought · 4 insiders
$0
sold · 0 insiders
−5.4%
vs their $1.73 cost
DateInsiderTypeValue
Oct 21, 2026
ADAR1 Capital Management, LLC
10%+ Owner
BUY$550.7K
Oct 20, 2026
ADAR1 Capital Management, LLC
10%+ Owner
BUY$405.7K
Oct 19, 2026
ADAR1 Capital Management, LLC
10%+ Owner
BUY$507.0K
Sep 16, 2026
Doogan Declan
Director
BUY$101.8K
Sep 15, 2026
Giordano Christopher Thomas
CEO
BUY$8.8K
Sep 11, 2026
STAAB THOMAS R II
Chief Financial Officer
BUY$11.0K
Sep 11, 2026
Giordano Christopher Thomas
CEO
BUY$11.3K
Sep 3, 2026
ADAR1 Capital Management, LLC
10%+ Owner
BUY$1.6M

Earnings setup

Estimates
Nov 10
reports in 14 days
−$0.36
EPS estimate, this quarter
+6%
estimate change, 90 days
4↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.36-$0.39–-$0.33+0.0%$0.00
Next Q-$0.38-$0.43–-$0.34+0.0%$0.00
Current FY-$1.45-$1.75–-$1.15+0.0%$0.00
Next FY-$1.50-$1.74–-$1.29+0.0%$0.00

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 21, 2026 Insider
ADAR1 Capital Management, LLC bought 331,979 shares
10%+ Owner @ $1.66 ($550.7K)
Oct 20, 2026 Insider
ADAR1 Capital Management, LLC bought 254,342 shares
10%+ Owner @ $1.60 ($405.7K)
Oct 19, 2026 Insider
ADAR1 Capital Management, LLC bought 336,528 shares
10%+ Owner @ $1.51 ($507.0K)
Oct 15, 2026 SEC
Millennium Management LLC filed an amended Schedule 13G disclosing a 3.6% passive stake in Tenax Therapeutics as of…
SC 13G/A — Impact 3/10
Oct 13, 2026 SEC
Sphera Funds Management Ltd. and related entities filed an amended Schedule 13G disclosing a 7.09% passive beneficial…
SC 13G/A — Impact 5/10
Oct 9, 2026 SEC
Dellora Investments LP filed an amended Schedule 13G disclosing a 6.4% passive stake in Tenax Therapeutics, up from a…
SC 13G/A — Impact 3/10
Sep 30, 2026 Short interest report
Short Interest: TENX up 30% to 7.2M shares
Settlement 2026-09-30 | Days to cover: 2.35 | ≈19.19% of shares outstanding (est.)
Aug 29, 2026 Press
Tenax Therapeutics presented additional Phase 3 LEVEL trial data for TNX-103 (oral levosimendan) in PH-HFpEF at ESC…
Impact 7/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 10, 2026
Earnings date
TENX Q3 2026 Earnings Scheduled — 2026-11-10
Recent
Sep 30, 2026
Short interest
Short Interest: TENX up 30% to 7.2M shares
Settlement 2026-09-30 | Days to cover: 2.35 | ≈19.19% of shares outstanding (est.)
Sep 15, 2026
Short interest
Short Interest: TENX down 41% to 5.5M shares
Settlement 2026-09-15 | Days to cover: 1.03 | ≈14.71% of shares outstanding (est.)
Sep 1, 2026
Press release
Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
CHAPEL HILL, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”)…
Aug 31, 2026
Short interest
Short Interest: TENX up 69% to 9.3M shares
Settlement 2026-08-31 | Days to cover: 1.12 | ≈24.79% of shares outstanding (est.)
Aug 29, 2026
FDA
Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026
In patients with a baseline 6MWD below the trial median of 333 meters, treatment with TNX-103 resulted in a 26.3-meter improvement compared to…

SecBot reports

17 filings · 4 press releases · 2 bullish · 0 bearish · 1 mixed · 14 neutral
All TENX filing & press-release reports (21)